Compare Ginkgo Bioworks Holdings Inc (DNA) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Union Pacific Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.22 (market cap $763.64M), while Union Pacific Corporation trades at $278 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 216.4× Ginkgo Bioworks Holdings Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Union Pacific Corporation for 105 Days on average.
| DNA | UNP | |
|---|---|---|
Market Cap | $763.64M | $165.27B |
Volume | 3,204,177 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $15.83 | $310.62 |
52-Week Low | $5.48 | $216.37 |
Typical Hold Time | 7 Days | 105 Days |
Enterprise Value | $865.59M | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Union Pacific (UNP) trades at $277.51, up 1.03% with a bullish technical signal and strong fundamental performance. The stock shows robust profitability with 28.85% net margins and 39.7% ROE, supported by consecutive earnings beats in Q1 and Q2 2026. Recent developments include the deployment of battery-electric locomotives and progress on the Norfolk Southern combination, while analyst consensus remains strongly positive with a $332.10 price target.
UNP presents a compelling investment case with strong operational execution and pricing power, though merger uncertainty and fuel cost pressures pose near-term risks. The stock's current valuation at 22.53 P/E offers reasonable upside to analyst targets, supported by consistent dividend payments and infrastructure advantages in the irreplaceable freight rail network.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
